The interaction between steroid hormones, human papillomavirus type 16, E6 oncogene expression, and cervical cancer

M. Moodley, S. Sewart, C. S. Herrington, R. Chetty, R. Pegoraro, J. Moodley

    Research output: Contribution to journalArticle

    12 Citations (Scopus)

    Abstract

    Various risk factors have been implicated in the causation of cervical cancer including human papillomavirus (HPV), the early genes (E6 and E7 ) of which encode the main transforming proteins. Studies have suggested that steroid hormones may enhance the expression of these genes leading to loss of p53 gene-mediated cell apoptosis. A total of 120 cervical tissue samples were obtained from patients with proven cervical cancer. Patients who used depo-medroxyprogesterone acetate steroid contraception were recruited as part of the steroid arm. Only HPV DNA type 16 samples were used for the study. Controls included three cell lines (CaSki, SiHa, & C33A) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal housekeeping gene. Of 120 patients, there were 111 patients with HPV type 16 identified. Of this number, RNA was present in 63 samples. There were 30 women (30/63) who used steroid contraception. In relation to patients who used contraception, HPV 16 E6 gene expression was present in 79% (n = 23) and 88% (n = 30) of steroid users compared to nonusers, respectively. In total there were 25 patients (40%) with expression of the HPV 16 E6*I gene and 30 patients with expression of the E6*II gene. There were 57% of steroid users (n = 17) who had expression of the E6*I/E6*II gene, compared to 52% (n = 17) of nonusers (P = 0.800). From a molecular level, this study does not confirm the role of injectable progesterones in cervical carcinogenesis.

    Original languageEnglish
    Pages (from-to)834-842
    Number of pages9
    JournalInternational Journal of Gynecological Cancer
    Volume13
    Issue number6
    DOIs
    Publication statusPublished - 2003

    Cite this

    Moodley, M. ; Sewart, S. ; Herrington, C. S. ; Chetty, R. ; Pegoraro, R. ; Moodley, J. . / The interaction between steroid hormones, human papillomavirus type 16, E6 oncogene expression, and cervical cancer. In: International Journal of Gynecological Cancer. 2003 ; Vol. 13, No. 6. pp. 834-842.
    @article{8f3033f105c74fdda58b09ef1809ad00,
    title = "The interaction between steroid hormones, human papillomavirus type 16, E6 oncogene expression, and cervical cancer",
    abstract = "Various risk factors have been implicated in the causation of cervical cancer including human papillomavirus (HPV), the early genes (E6 and E7 ) of which encode the main transforming proteins. Studies have suggested that steroid hormones may enhance the expression of these genes leading to loss of p53 gene-mediated cell apoptosis. A total of 120 cervical tissue samples were obtained from patients with proven cervical cancer. Patients who used depo-medroxyprogesterone acetate steroid contraception were recruited as part of the steroid arm. Only HPV DNA type 16 samples were used for the study. Controls included three cell lines (CaSki, SiHa, & C33A) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal housekeeping gene. Of 120 patients, there were 111 patients with HPV type 16 identified. Of this number, RNA was present in 63 samples. There were 30 women (30/63) who used steroid contraception. In relation to patients who used contraception, HPV 16 E6 gene expression was present in 79{\%} (n = 23) and 88{\%} (n = 30) of steroid users compared to nonusers, respectively. In total there were 25 patients (40{\%}) with expression of the HPV 16 E6*I gene and 30 patients with expression of the E6*II gene. There were 57{\%} of steroid users (n = 17) who had expression of the E6*I/E6*II gene, compared to 52{\%} (n = 17) of nonusers (P = 0.800). From a molecular level, this study does not confirm the role of injectable progesterones in cervical carcinogenesis.",
    author = "M. Moodley and S. Sewart and Herrington, {C. S.} and R. Chetty and R. Pegoraro and J. Moodley",
    year = "2003",
    doi = "10.1111/j.1525-1438.2003.13380.x",
    language = "English",
    volume = "13",
    pages = "834--842",
    journal = "International Journal of Gynecological Cancer",
    issn = "1048-891X",
    publisher = "Lippincott, Williams & Wilkins",
    number = "6",

    }

    The interaction between steroid hormones, human papillomavirus type 16, E6 oncogene expression, and cervical cancer. / Moodley, M. ; Sewart, S. ; Herrington, C. S. ; Chetty, R. ; Pegoraro, R. ; Moodley, J. .

    In: International Journal of Gynecological Cancer, Vol. 13, No. 6, 2003, p. 834-842.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - The interaction between steroid hormones, human papillomavirus type 16, E6 oncogene expression, and cervical cancer

    AU - Moodley, M.

    AU - Sewart, S.

    AU - Herrington, C. S.

    AU - Chetty, R.

    AU - Pegoraro, R.

    AU - Moodley, J.

    PY - 2003

    Y1 - 2003

    N2 - Various risk factors have been implicated in the causation of cervical cancer including human papillomavirus (HPV), the early genes (E6 and E7 ) of which encode the main transforming proteins. Studies have suggested that steroid hormones may enhance the expression of these genes leading to loss of p53 gene-mediated cell apoptosis. A total of 120 cervical tissue samples were obtained from patients with proven cervical cancer. Patients who used depo-medroxyprogesterone acetate steroid contraception were recruited as part of the steroid arm. Only HPV DNA type 16 samples were used for the study. Controls included three cell lines (CaSki, SiHa, & C33A) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal housekeeping gene. Of 120 patients, there were 111 patients with HPV type 16 identified. Of this number, RNA was present in 63 samples. There were 30 women (30/63) who used steroid contraception. In relation to patients who used contraception, HPV 16 E6 gene expression was present in 79% (n = 23) and 88% (n = 30) of steroid users compared to nonusers, respectively. In total there were 25 patients (40%) with expression of the HPV 16 E6*I gene and 30 patients with expression of the E6*II gene. There were 57% of steroid users (n = 17) who had expression of the E6*I/E6*II gene, compared to 52% (n = 17) of nonusers (P = 0.800). From a molecular level, this study does not confirm the role of injectable progesterones in cervical carcinogenesis.

    AB - Various risk factors have been implicated in the causation of cervical cancer including human papillomavirus (HPV), the early genes (E6 and E7 ) of which encode the main transforming proteins. Studies have suggested that steroid hormones may enhance the expression of these genes leading to loss of p53 gene-mediated cell apoptosis. A total of 120 cervical tissue samples were obtained from patients with proven cervical cancer. Patients who used depo-medroxyprogesterone acetate steroid contraception were recruited as part of the steroid arm. Only HPV DNA type 16 samples were used for the study. Controls included three cell lines (CaSki, SiHa, & C33A) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal housekeeping gene. Of 120 patients, there were 111 patients with HPV type 16 identified. Of this number, RNA was present in 63 samples. There were 30 women (30/63) who used steroid contraception. In relation to patients who used contraception, HPV 16 E6 gene expression was present in 79% (n = 23) and 88% (n = 30) of steroid users compared to nonusers, respectively. In total there were 25 patients (40%) with expression of the HPV 16 E6*I gene and 30 patients with expression of the E6*II gene. There were 57% of steroid users (n = 17) who had expression of the E6*I/E6*II gene, compared to 52% (n = 17) of nonusers (P = 0.800). From a molecular level, this study does not confirm the role of injectable progesterones in cervical carcinogenesis.

    U2 - 10.1111/j.1525-1438.2003.13380.x

    DO - 10.1111/j.1525-1438.2003.13380.x

    M3 - Article

    VL - 13

    SP - 834

    EP - 842

    JO - International Journal of Gynecological Cancer

    JF - International Journal of Gynecological Cancer

    SN - 1048-891X

    IS - 6

    ER -